BioRestorative Therapies, Inc. creates medical procedures using adult stem cells that are not derived from embryos. These procedures allow patients to undergo cellular-based treatments using minimally invasive techniques.
Both a program to treat metabolic issues based on stem cells found in brown fat and technology to treat disc injuries such as bulging and herniation are currently in the development stages at the company.
The company is presently developing a program called ThermoStem, which will involve the use of brown fat as part of a cell-based treatment for hypertension, obesity, and other metabolic disorders, as well as cardiac deficiencies and type 2 diabetes.
Additionally, the company is conducting research into stem cells, as well as several genes, proteins, and/or treatment approaches that have been linked to these diseases and conditions. Insights Care Magazine has named BioRestorative Therapies, Inc., a company in the life sciences industry, as one of the ten most creative regenerative medicine companies in 2022 for its work with adult stem cell-based therapies.
This news was just recently announced by BioRestorative Therapies, Inc., the company that made the announcement. BioRestorative Therapies, Inc. was selected to receive this honor for its work. Insights Care is a specialized publication that reports on recent happenings in biotechnology and healthcare.
The CEO of BioRestorative Therapies, Lance Alstodt, is featured in a news article that details the company’s rise from Chapter 11 reorganization to a successful capital raise and uplisting on the Nasdaq.On this occasion, Lance Alstodt said he is humbled to be included among the top ten most forward-thinking firms in the field of regenerative medicine.
This is a direct result of the dedication and perseverance of the BioRestorative staff. BioRestorative focus in 2022 will be on carrying out and delivering on its clinical plans. Mr. Alstodt remarked Everyone on the team is working together to make this happen and it’s possible that BRTX stock prices will fluctuate more rapidly.
The company’s lead therapeutic candidate, BRTX-100, for the treatment of chronic lumbar disc disease has been authorised for a Phase 2 FDA research trial. This remedy is for people whose pain has not responded to less invasive treatments and who may eventually require surgical intervention.
Brown adipose depots are present in humans and play a role in maintaining metabolic homeostasis; BAT is meant to simulate these cells. Preliminary research suggests that higher levels of brown fat in the body contribute to greater calorie expenditure and less lipids and glucose levels.
Scientists revealed that people having more level of brown fat were less likely to become overweight or develop diabetes.BioRestorative Therapies, Inc. is in the business of developing therapeutic products through the application of cell and tissue protocols, with a primary focus on adult stem cells.
In August 2011, the company changed its name to BioRestorative Therapies, Inc. from Stem Cell Assurance, Inc. BioRestorative Therapies, Inc. was founded in 1997 and is headquartered in Melville, New York.BRTX stock, according to analysts will go to new high soon.
To increase his direct ownership of his company by 0.33 percent to 180,921 units, Alstodt Lance spent $2,238 to purchase 600 BRTX stock (at a price of $3.73 per share).
Treating metabolic disorders and diseases of the discs and spine, respectively, is the primary focus of this company’s two primary initiatives.Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania, respectively, have signed three separate research and development, research collaboration, and research agreement contracts with BioRestorative Therapies, Inc.
